Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.
Ferraris
Dana V
DV
Johns Hopkins University Brain Science Institute, 855 N. Wolfe Street, Baltimore, Maryland 21205, USA. Dferrar2@jhmi.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D001665:Binding Sites; D055808:Drug Discovery; D004345:Drug Industry; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000266:history / Q000494:pharmacology; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007511:Ischemia / Q000188:drug therapy / Q000201:enzymology; D009536:Niacinamide / Q000378:metabolism; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D012106:Research
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D009536:Niacinamide